Search

Your search keyword '"Gralow J"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Gralow J" Remove constraint Author: "Gralow J"
268 results on '"Gralow J"'

Search Results

1. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

2. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

3. Cancer research across Africa: a comparative bibliometric analysis.

7. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

10. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy±everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

12. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

13. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

14. Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS)

15. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

17. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

18. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

20. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

21. Adjuvant bisphosphonate treatment in early breast cancer:meta-analyses of individual patient data from randomised trials

22. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor - Induced musculoskeletal pain: SWOG S0927

23. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

24. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

26. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

27. Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

28. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

32. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials

33. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

34. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

36. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

37. Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

38. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

39. Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study

40. Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

43. 5025 POSTER DISCUSSION Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) – Results of an Exploratory Analysis by Prior Therapy

44. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831.

45. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.

47. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial.

50. Variants in the BRCA1/Fanconi-Anemia Repair Pathway and Taxane-Induced Neuropathy in SWOG S0221.

Catalog

Books, media, physical & digital resources